Mylan to launch generic version of Nuvigil in 2016

Drug maker reaches settlement with Teva

PITTSBURGH — Mylan plans to start selling a generic version of a drug for sleep disorders starting in June 2016, under a deal with Teva announced Monday.

Mylan said it had settled with Teva over the former's generic version of Nuvigil (armodafinil) tablets, a drug used to treat sleepiness related to sleep apnea, narcolepsy and shift work disorder.

Mylan plans to sell the generic in the 50-mg, 150-mg and 250-mg strengths. Under the opinion that it was the first company to successfully file for Food and Drug Administration approval of the drug, Mylan said it expects to receive 180 days of market exclusivity in which to directly compete with Teva's product.

Nuvigil had sales of $296 million in 2011, according to IMS Health. Teva has owned rights to the drug since it finalized its acquisition of Cephalon in October 2011.


Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.

Login or Register to post a comment.